Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Jeffrey Dierks Sells 10,507 Shares of Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jeffrey Dierks also recently made the following trade(s):

• On Tuesday, October 29th, Jeffrey Dierks sold 21,496 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.47, for a total value of $869,943.12.

Harmony Biosciences Trading Up 4.4 %

Shares of Harmony Biosciences stock opened at $38.54 on Friday. The firm has a 50-day simple moving average of $34.34 and a two-hundred day simple moving average of $34.78. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The company has a market cap of $2.20 billion, a P/E ratio of 18.27, a price-to-earnings-growth ratio of 0.49 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. During the same quarter in the prior year, the firm posted $0.63 EPS. Harmony Biosciences’s quarterly revenue was up 16.0% compared to the same quarter last year. As a group, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Harmony Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. ARS Investment Partners LLC acquired a new position in Harmony Biosciences during the fourth quarter worth $841,000. Avanza Fonder AB purchased a new stake in shares of Harmony Biosciences during the fourth quarter worth about $145,000. Hennion & Walsh Asset Management Inc. raised its position in shares of Harmony Biosciences by 38.3% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 75,072 shares of the company’s stock worth $2,583,000 after purchasing an additional 20,798 shares during the last quarter. Mendota Financial Group LLC lifted its stake in Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after buying an additional 965 shares in the last quarter. Finally, CWA Asset Management Group LLC boosted its holdings in Harmony Biosciences by 27.0% in the 4th quarter. CWA Asset Management Group LLC now owns 18,279 shares of the company’s stock worth $629,000 after buying an additional 3,883 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Ratings Changes

HRMY has been the topic of several research reports. Mizuho increased their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a research note on Monday. Raymond James restated an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a research report on Thursday, October 10th. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Finally, Cantor Fitzgerald boosted their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.